The blood glucose-lowering agents such as metformin, sulfonylurea derivatives, and insulin all can improve glycemic control in patients with T2DM, but these agents have limited or no effect on the associated CV risk factors accompanying T2DM including dyslipidemia, hypertension, and obesity. Here, INS is linked to type 2 diabetes mellitus.